Cobenfy (xanomeline/trospium) - BMS
Psychosis symptoms associated with AD improve with short- and long-term open-label KarXT treatment (CTAD 2026) - Sep 26, 2026 - Abstract #OC21; Pres time: Nov 18, 2026; 09:00 AM - 09:15 AM; No abstract available 
Clinical • CNS Disorders • Psychiatry
https://www.ctad-alzheimer.com/sites/www.ctad-alzheimer.com/files/medias/documents/Preliminary_Program_CTAD26_2409.pdf
 
Jeffrey CUMMINGS1; Ninoslav MIMICA2; Ashish SHAH3; Janette GARNER3; Codrin LUNGU3; Antonio OLIVEROS-CID4; George GROSSBERG5
 
Sep 26, 2026
 
Prev Next